Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189075 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sigrid Ravn Berg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Proteomics, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Liaison Committee between the Central Norway regional Health Authority and Norwegian University of Science and Technology, the Cancer Fund at St. Olavs Hospital, Trondheim, NTNU.
Abstract (Originalsprache)
Isocitrate dehydrogenase 1 (IDH1) mutations are key drivers of glioma biology, influencing tumor aggressiveness and treatment response. To elucidate their molecular impact, we performed proteome analysis on patient-derived (PD) and U87MG glioma cell models with either mutant or wild-type IDH1. We quantified over 6000 protein groups per model, identifying 1594 differentially expressed proteins in PD-AS (IDH1MUT) vs. PD-GB (IDH1WT) and 904 in U87MUT vs. U87WT. Both IDH1MUT models exhibited enhanced MHC antigen presentation and interferon signaling, indicative of an altered immune microenvironment. However, metabolic alterations were model-dependent: PD-AS cells shifted toward glycolysis and purine salvage, while U87MUT cells retained oxidative phosphorylation, potentially due to D2-hydroxyglutarate (2OHG)-mediated HIF1A stabilization. We also observed a predominance of downregulated DNA repair proteins in IDH1MUT models, particularly those involved in homologous recombination. In contrast, RB1 and ASMTL were strongly upregulated in both IDH1MUT models, implicating them in DNA repair and cellular stress responses. We also found distinct expression patterns of proteins regulating histone methylation in IDH1MUT cells, favoring increased methylation of H3K4, H3K9, and H3K36. A key driver of this may be the upregulation of SETD2 in PD-AS, an H3K4 and H3K36 trimethyltransferase linked to the recruitment of HIF1A as well as DNA mismatch repair proteins. This study uncovers candidate biomarkers and pathways relevant to glioma progression and therapeutic targeting, but also underscores the complexity of predicting glioma pathogenesis and treatment responses based on IDH1 mutation status. While proteome profiling provides valuable insights, a comprehensive understanding of IDH1MUT gliomas will likely require integrative multi-omics approaches, including DNA/RNA methylation profiling, histone and protein post-translational modification analyses, and targeted DNA damage and repair assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
- Clinic of Laboratory Medicine, St. Olavs Hospital, 7491 Trondheim, Norway.
- The Proteomics and Modomics Core Facility, PROMEC, at NTNU and the Central Norway Regional Health Authority, 7491 Trondheim, Norway.
- Department of Microbiology, Oslo University Hospital and University of Oslo, 0372 Oslo, Norway.
- Norway Centre of Embryology (CRESCO), University of Oslo, 0313 Oslo, Norway.
- Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.
ORCID-Profile: Alessandro Brambilla, Animesh Sharma, Nina Beate Liabakk, Miroslava Kissova, Miquel Arano Barenys, Magnar Bjørås, Sverre Helge Torp, Geir Slupphaug
Förderung
- The Liaison Committee between the Central Norway regional Health Authority and Norwegian University of Science and Technology
- the Cancer Fund at St. Olavs Hospital, Trondheim
- NTNU
- the Liaison Committee for Education, Research and Innovation in Central Norway
- RCN INFRASTRUKTUR-program
- the PRIDE and Norstore/Notur projects
Zitieren
APA
Ravn Berg, S., Brambilla, A., Hagen, L., Sharma, A., Vågbø, C. B., Liabakk, N. B., Kissova, M., Arano Barenys, M., Bjørås, M., Torp, S. H., & Slupphaug, G. (2025). Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189075
Vancouver
Ravn Berg S, Brambilla A, Hagen L, Sharma A, Vågbø CB, Liabakk NB, et al. Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189075
BibTeX
@article{RavnBerg2025,
author = {Ravn Berg, Sigrid and Brambilla, Alessandro and Hagen, Lars and Sharma, Animesh and Vågbø, Cathrine Broberg and Liabakk, Nina Beate and Kissova, Miroslava and Arano Barenys, Miquel and Bjørås, Magnar and Torp, Sverre Helge and Slupphaug, Geir},
title = {Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189075}
}
EUVIMED